- Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data TranscriptFeb 08, 2024
- Adverum Biotechnologies Inc at HC Wainwright Ophthalmology Virtual Conference TranscriptAug 16, 2023
- Adverum Biotechnologies Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Adverum Biotechnologies Inc ADVM-022 Update Call TranscriptJul 22, 2021
- Q4 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMar 01, 2021€109 (+2.83%)Earnings
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptNov 14, 2020
- Q2 2020 Adverum Biotechnologies Inc Earnings Call TranscriptAug 10, 2020€157 (+4.67%)Earnings
- Adverum Biotechnologies Inc Annual Shareholders Meeting TranscriptJun 23, 2020
- Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Q1 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMay 28, 2020€188 (+8.67%)Earnings
- Adverum Biotechnologies Inc to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD Call TranscriptMay 04, 2020
- Q4 2019 Adverum Biotechnologies Inc Earnings Call TranscriptMar 12, 2020€76 (-3.80%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptFeb 09, 2020
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Adverum Biotechnologies Inc Earnings Call TranscriptNov 07, 2019€72Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial TranscriptOct 12, 2019
- Adverum Biotechnologies Inc to Review Data Presented at Retina Society 2019 Conference Call TranscriptSep 12, 2019
- Q2 2019 Adverum Biotechnologies Inc Earnings Call TranscriptAug 08, 2019€103.68 (-2.78%)Earnings
Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay, thank you, everyone, and welcome to 3:50 p.m. session on Day 3 of the Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I'm a senior analyst covering European and U.S. biopharma for the firm. It's my great pleasure to be hosting Adverum today for our fireside chat. We'll have about 40 minutes to get to know the company and ask questions, and I've got the pleasure of introducing 3 members of the senior management team, CEO, Leone Patterson; Chief Medical Officer, Aaron Osborne; and Chief Financial Officer, Thomas Leung.
So as we go into our fireside chat, let me first welcome Adverum to our conference. Hopefully, we can do this in-person next year out in, hopefully, sunny Southern California and sort of look forward to your participation in years to come.
For the audience, for those of you who may not know the Adverum story, maybe we can start by asking the management team and maybe, Leone, I'll pass it over to you, by just giving us kind
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)